VRN101099 / Voronoi - LARVOL DELTA

VRN101099: A novel treatment option for HER2-driven cancer patients, overcoming T-DXd resistance and brain metastases (AACR 2025) - "In intracranial xenograft models, VRN101099 demonstrated superior anti-tumor efficacy to tucatinib, neratinib, zongertinib, trastuzumab, and T-DXd. In conclusion, VRN101099 is a promising HER2-selective TKI with a favorable profile including potency, tolerability, and brain permeability. This identifies VRN101099 as a potential novel systemic treatment option for patients with HER2-driven cancers, particularly those with brain metastases or those who have progressed after or failed with T-DXd."

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • EGFR • HER-2

A Phase 1 Study of VRN101099 in Patients With HER2-Positive Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Voronoi, Inc

New P1 trial • Oncology • Solid Tumor

Voronoi, solid tumor target 'VRN101099' Australian clinical phase 1 IND approved [Google translation] (Yakup Shinmoon) - "Voronoi has received approval for the phase 1 clinical trial plan for 'VRN101099' from the Australian Human Research Ethics Committee...the clinical trial will be conducted at five institutions in Australia and Korea with 72 patients with HER2-positive solid tumors...In this clinical trial, the company plans to confirm the maximum tolerated dose and dose-limiting toxicity of the drug and establish the recommended phase 2 dose (RP2D)...'The 'expected end date of the clinical trial' is approximately 36 months from the date of approval of the clinical plan.'....The company applied for the clinical trial on November 19, 2024."

New P1 trial • Trial completion date • Solid Tumor • HER-2

VRN101099: a novel oral treatment option for patients with advanced solid tumors including brain metastasis driven by HER2 amplification or HER2-activating mutations even with T-DXd resistance (EORTC-NCI-AACR 2024) - "Thanks to its high brain permeability and non-substrate of BCRP, VRN101099 exhibited superior intracranial anti-tumor efficacy compared to current therapeutic options, such as tucatinib, neratinib, trastuzumab, and T-DXd. VRN101099 presents a novel systemic treatment option for patients with HER2-driven cancer, particularly those with brain metastasis or who have progressed after or discontinued T-DXd. The first-in-human study of VRN101099 is expected at the end of 2024."

Clinical • Late-breaking abstract • Metastases • Breast Cancer • Colon Cancer • Colorectal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • HER-2

Preclinical study of VRN101099, a Brain Permeable HER2-Selective Irreversible Kinase Inhibitor for HER2 Positive Metastatic Breast Cancer (SABCS 2023) - No abstract available

Metastases • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers (SABCS 2022) - "While T-DXd showed positive results in HER2-positive breast cancer brain metastasis (BCBM), its activity and blood-brain barrier (BBB) permeability in active BCBM need to be further validated (TUXEDO-1 included 15 patients with active brain metastasis). Tucatinib plus Trastuzumab and Capecitabine triplet showed efficacy in patients with brain metastasis, but Tucatinib alone has poor BBB penetration...In summary, VRN101099 is a brain penetrant, orally bioavailable, irreversible, and highly selective inhibitor of HER2 with therapeutic potential in HER2-positive BCBM. These data support the clinical development of VRN101099 in HER2-driven cancers."

Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • EGFR • HER-2